April 2021 // Investment: Synendos Series A Extension

Synendos Therapeutics is thrilled to announce an extension to the Series A financing with the addition of Ysios Capital to its syndicate of European investors. Ysios Capital’s contribution brings the total raised to CHF 24 million, following a Series A financing co-led by Kurma Partners and Sunstone Life Science Ventures announced in November 2020.

In addition, Synendos Therapeutics is delighted to announce securing a prestigious Eurostars grant (EU funding scheme) to expand proof-of-concept preclinical studies for PTSD and the appointment of Professor Jutta Heim as Chair to the Board.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...

GET IN TOUCH